renal cell carcinoma

Summary

Summary: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Top Publications

  1. doi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
  2. doi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
  3. doi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
  4. doi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
  5. doi Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 28:2144-50. 2010
  6. doi Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Lancet 373:1119-32. 2009
  7. pmc Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 28:2137-43. 2010
  8. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
  9. doi Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    Jennifer S Ko
    Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
    Clin Cancer Res 15:2148-57. 2009
  10. ncbi Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Genet 30:406-10. 2002

Detail Information

Publications332 found, 100 shown here

  1. doi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
    ..and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)...
  2. doi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ..data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.
  3. doi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
    ..trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors...
  4. doi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with ..
  5. doi Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival
    Bernard Escudier
    Unité Immunothérapie, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 28:2144-50. 2010
    A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC). Here, we report overall survival (OS) data.
  6. doi Renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Lancet 373:1119-32. 2009
    Considerable progress has been made in the treatment of patients with renal cell carcinoma, with innovative surgical and systemic strategies revolutionising the management of this disease...
  7. pmc Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 28:2137-43. 2010
    Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC...
  8. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  9. doi Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    Jennifer S Ko
    Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
    Clin Cancer Res 15:2148-57. 2009
    Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induce T-cell suppression...
  10. ncbi Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Genet 30:406-10. 2002
    ..We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6)...
  11. ncbi Sorafenib in advanced clear-cell renal-cell carcinoma
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 356:125-34. 2007
    ..We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma...
  12. pmc Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes
    Paulo C Rodriguez
    Department of Microbiology, Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 69:1553-60. 2009
    ..suppressor cells (MDSC) producing arginase I are increased in the peripheral blood of patients with renal cell carcinoma (RCC)...
  13. pmc Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma
    Huiqing Liu
    BioMaPS Institute, Rutgers University, Piscataway, NJ 08854, USA
    BMC Syst Biol 4:51. 2010
    ..Putative mRNA targets of microRNA identified from seed sequence matches are available in many databases. However, such matches have a high false positive rate and cannot identify tissue specificity of regulation...
  14. pmc The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    Inhibitors of TORC1 have been shown to be active in patients with metastatic renal cell carcinoma (RCC)...
  15. doi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ..potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib.
  16. doi MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens
    Lihong Weng
    Department of Pathology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
    J Pathol 222:41-51. 2010
    b>Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality...
  17. pmc Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer...
  18. pmc Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:3584-90. 2009
    ..superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported.
  19. ncbi Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
    Nicolette K Janzen
    Department of Urology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Urol Clin North Am 30:843-52. 2003
    ..Factors including patient comorbidities and patient willingness to pursue aggressive management in the event of recurrence may alter the follow-up for each individual...
  20. doi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response.
  21. pmc Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma
    Yohei Horikawa
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7956-62. 2008
    ..Compelling evidence has shown that miRNAs are involved in cancer initiation and progression. We hypothesized that genetic variations of the miRNA machinery genes could be associated with the risk of renal cell carcinoma.
  22. doi Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells
    Yong Zhong
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China
    Cancer Lett 299:150-60. 2010
    ..In this study, we sought to enrich CSCs from the renal cell carcinoma (RCC) cell line SK-RC-42 using the sphere culture system and characterize their immunophenotype...
  23. doi Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique
    Clizia Chinello
    Department of Experimental Medicine, University of Milano Bicocca, Monza, Italy
    Urology 75:842-7. 2010
    ..related diagnostic markers that are able to better discriminate healthy subjects from patients affected by renal cell carcinoma (ccRCC). Renal cell carcinoma is the most common malignancy of the kidney...
  24. doi Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure
    Pascal Hajj
    Department of Urology, Bicetre University Hospital, Universite Paris Sud, Le Kremlin Bicetre, France
    Urology 74:631-4. 2009
    To study the prevalence and the characteristics of renal cell carcinoma (RCC) in patients with autosomal dominant polycystic kidney disease (ADPKD) in our series.
  25. ncbi Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma
    Augusto C Ochoa
    Stanley S Scott Cancer Center and Department of Pediatrics, Louisiana State University Health Sciences Center, 533 Bolivar Street, New Orleans, LA 70112, USA
    Clin Cancer Res 13:721s-726s. 2007
    ..increase in MDSC could explain the molecular alterations and dysfunction found in T cells of patients with renal cell carcinoma (RCC)...
  26. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  27. pmc FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma
    Virginia E Kwitkowski
    Division of Drug Oncology Products, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U S Food and Drug Administration, Silver Spring, Maryland 20993 0002, USA
    Oncologist 15:428-35. 2010
    ..Administration (FDA)'s approval of temsirolimus (Torisel), on May 30, 2007, for the treatment of advanced renal cell carcinoma (RCC). Information provided includes regulatory history, study design, study results, and literature review...
  28. pmc Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells
    Hong Xin
    Divisions of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Cancer Res 69:2506-13. 2009
    ..is used as an antiangiogenic agent for the treatment of several types of cancer, including metastatic renal cell carcinoma (RCC). Sunitinib was shown to positively change the immunosuppressive phenotype in RCC patients...
  29. pmc Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma
    Jinliang Xing
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Natl Cancer Inst 100:1104-12. 2008
    ..b>Renal cell carcinoma accounts for 85% of all renal cancers...
  30. ncbi HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
    Jennifer S Isaacs
    Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Cell 8:143-53. 2005
    ..Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels...
  31. ncbi C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 110:1241-7. 2007
    C-reactive protein (CRP) represents a promising prognostic variable in patients with sporadic renal cell carcinoma (RCC)...
  32. doi Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma
    Hanne Krogh Jensen
    Department of Oncology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    J Clin Oncol 27:4709-17. 2009
    We have previously demonstrated a significant negative impact of intratumoral neutrophils in metastatic renal cell carcinoma. This study assessed intratumoral neutrophils in localized clear cell renal cell carcinoma (RCC).
  33. ncbi Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
    L Schmidt
    Intramural Research Support Program, SAIC Frederick, MD, USA
    Nat Genet 16:68-73. 1997
    ..The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas...
  34. ncbi Identification of novel target genes by an epigenetic reactivation screen of renal cancer
    Inmaculada Ibanez de Caceres
    Departments of Surgical Oncology and Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 66:5021-8. 2006
    ....
  35. ncbi Rising incidence of renal cell cancer in the United States
    W H Chow
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892 7240, USA
    JAMA 281:1628-31. 1999
    Clinical surveys have revealed that incidental detection of renal cell carcinoma is rising because of increased use of imaging procedures.
  36. ncbi Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
    Brian I Rini
    Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Cancer 106:566-75. 2006
    ..COX-2 is expressed in the majority of renal cell carcinoma (RCC) tumors and correlates with stage, grade, and microvessel density...
  37. pmc Annexin II represents metastatic potential in clear-cell renal cell carcinoma
    Y Ohno
    Department of Urology, Tokyo Medical University, Tokyo, Japan
    Br J Cancer 101:287-94. 2009
    ..The purpose of this study was to assess ANX2 expression in clear-cell (cc) renal cell carcinoma (RCC).
  38. doi Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Edit Remak
    Health Care Analytics, United BioSource Corp, 20 Bloomsbury Square, London WC1A 2NS, United Kingdom
    J Clin Oncol 26:3995-4000. 2008
    To assess the cost effectiveness and cost utility of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and interleukin-2 (IL-2) from a US societal perspective.
  39. ncbi CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma
    Linhui Wang
    The Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, PR China
    Oncol Rep 22:1333-9. 2009
    b>Renal cell carcinoma (RCC) shows organ-specific metastasis...
  40. ncbi Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B
    Balaji Krishnamachary
    Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 66:2725-31. 2006
    ..Thus, HIF-1 contributes to the epithelial-mesenchymal transition in VHL-null RCC by indirect repression of E-cadherin...
  41. doi Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma
    Davit Mosashvilli
    Department of Urology, University Hospital Bonn, Bonn, Germany
    Cancer Sci 101:2664-9. 2010
    ..histone H3 acetylation [H3Ac] and total histone H4 acetylation [H4Ac]) were determined in patients with renal cell carcinoma (RCC) using immunohistochemistry in a tissue micro array with 193 RCC and 10 oncocytoma specimens...
  42. ncbi Gene signatures of progression and metastasis in renal cell cancer
    Jon Jones
    Beth Israel Deaconess Medical Center Genomics Center and Dana Farber Harvard Cancer Center Proteomics Core, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:5730-9. 2005
    ..To address the progression, metastasis, and clinical heterogeneity of renal cell cancer (RCC)...
  43. ncbi Impact of immune parameters on long-term survival in metastatic renal cell carcinoma
    Frede Donskov
    Department of Oncology, Aarhus University Hospital, Aarhus C, Denmark
    J Clin Oncol 24:1997-2005. 2006
    The purpose of this study was to evaluate the impact of immunologic prognostic factors in combination with established clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC).
  44. ncbi The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis
    Essam M Elsamman
    Department of Urology and Department of Anatomy and Cell Biology, The University of Tokushima Graduate School Institute of Health Biosciences, Tokushima, Japan
    BJU Int 98:668-73. 2006
    To analyse the gene expression level of prostate stem cell antigen (PSCA) in human clear cell renal cell carcinoma (CC-RCC) and its relationship with conventional clinicopathological manifestations, to evaluate its prognostic value for ..
  45. pmc The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis
    K Dreijerink
    Laboratory of Immunobiology and Intramural Research Support Program, Science Applications International Corporation, National Cancer Institute, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 98:7504-9. 2001
    ..Mutant RASSF1A had reduced growth suppression activity significantly. These data suggest that RASSF1A is the candidate renal TSG gene for the 3p21.3 region...
  46. ncbi Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma
    Dorina Veliceasa
    Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    FEBS J 274:6365-77. 2007
    Angiogenic switch in renal cell carcinoma (RCC) is attributed to the inactivation of the von Hippel-Lindau tumor suppressor, stabilization of hypoxia inducible factor-1 transcription factor and increased vascular endothelial growth factor...
  47. doi Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ..carbonic anhydrase IX (CAIX) expression and histological features for predicting the outcome in patients with metastatic clear-cell renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy.
  48. pmc Tumor-to-tumor metastasis: Renal cell carcinoma metastatic to papillary carcinoma of thyroid-report of a case and review of the literature
    Olga L Bohn
    Department of Pathology, MetroHealth Medical Center Case Western Reserve University, Cleveland, OH 44109, USA
    Head Neck Pathol 3:327-30. 2009
    Metastatic disease to thyroid gland is a rare event. Although renal cell carcinoma (RCC) has been reported to metastasize the thyroid gland, metastatic RCC to a thyroid neoplasm is very unusual...
  49. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with ..
  50. doi Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    Walter M Stadler
    Department of Medicine, University of Chicago Medical Center, Chicago, Illinois
    Cancer 116:1272-80. 2010
    The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) program made sorafenib available to patients with advanced renal cell carcinoma (RCC) before regulatory approval.
  51. ncbi Differentiation of subtypes of renal cell carcinoma on helical CT scans
    Jeong Kon Kim
    Department of Radiology, Asan Medical Center, University of Ulsan, 388 1 Poongnap dong, Songpa Gu, Seoul, 138 736, South Korea
    AJR Am J Roentgenol 178:1499-506. 2002
    The purpose of our study was to differentiate subtypes of renal cell carcinoma on helical CT scans.
  52. ncbi Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival
    Yasuyoshi Miyata
    Department of Urology, Nagasaki University School of Medicine, Japan
    Clin Cancer Res 9:1741-9. 2003
    ..However, the relationships between COX-2 expression and these biological processes, clinicopathological features, and survival rate in patients with renal cell carcinoma are not clear.
  53. doi Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
    Kiran Gupta
    Abt Associates Inc, HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Cancer Treat Rev 34:193-205. 2008
    b>Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis...
  54. ncbi Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer
    Seiichiro Ozono
    Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
    Jpn J Clin Oncol 34:82-5. 2004
    This study was conducted to examine the natural history of renal cell carcinoma (RCC).
  55. pmc Tumor size is associated with malignant potential in renal cell carcinoma cases
    R Houston Thompson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 181:2033-6. 2009
    ..We evaluated our experience with renal cortical tumors to determine whether tumor size is associated with malignant histology and/or nuclear grade...
  56. doi Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
    ..are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated.
  57. ncbi Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma
    Giovanni C Cesana
    Tumor Immunology Laboratory, Department of Surgery and Biostatistics, Columbia University Medical Center, New York, NY 10032, USA
    J Clin Oncol 24:1169-77. 2006
    To characterize the number and functional status of CD4+CD25+ regulatory T cells (Tregs) in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) treated with high-dose bolus interleukin-2 (IL-2).
  58. pmc Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma
    Jie Lin
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 31:1805-12. 2010
    ..single-nucleotide polymorphisms (SNPs) in microRNAs (miRNAs)-related genes on survival and recurrence among renal cell carcinoma (RCC) patients. During a median follow-up of 21...
  59. doi Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
    Dorothy A White
    Memorial Sloan Kettering Cancer Center, Pulmonary Medicine, New York, NY 10021, USA
    Am J Respir Crit Care Med 182:396-403. 2010
    ..Objectives: To assess the incidence, radiographic patterns, management, and outcome of pneumonitis in patients with advanced renal cell carcinoma receiving everolimus.
  60. doi Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients
    Sei Naito
    Department of Urology, Yamagata University, Yamagata 951 8510, Japan
    Eur Urol 57:317-25. 2010
    Incidence rate of renal cell carcinoma (RCC) differs among countries. The rates of Asian countries are lower than those of countries in North America or Europe but are exceptionally high in Japanese males...
  61. doi Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma
    M A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 29:5724-8. 2010
    The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence...
  62. doi Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    Sergei Kusmartsev
    Department of Urology, College of Medicine, University of Florida, Gainesville, Florida 32610 0247, USA
    Clin Cancer Res 14:8270-8. 2008
    ..immunosuppression remains a significant obstacle that limits the efficacy of biological therapy for renal cell carcinoma. Here we evaluate the role of CD33 myeloid-derived suppressor cells (MDSC) in the regulation of T-cell ..
  63. ncbi Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial
    Chaitanya R Divgi
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 8:304-10. 2007
    ..We aimed to assess whether iodine-124-labelled antibody chimeric G250 ((124)I-cG250) PET predicts clear-cell renal carcinoma, the most common and aggressive renal tumour...
  64. ncbi Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study
    Zhong Jiang
    University of Massachusetts Medical Center, Department of Pathology, Worcester, MA, USA
    Lancet Oncol 7:556-64. 2006
    ..We aimed to investigate whether IMP3, an oncofetal RNA-binding protein, can be used as a biomarker to predict metastasis and prognosis of renal-cell carcinoma...
  65. doi Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells
    Longxin Wang
    Department of Urology, Xijing Hospital, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi an, Shaanxi Province, China
    Clin Cancer Res 16:164-73. 2010
    ....
  66. ncbi Liver resection for metastases from renal cell carcinoma
    Armin Thelen
    Departmant of General, Visceral and Transplantation Surgery, Campus Virchow Klinikum, Charite Universitaetsmedizin Berlin, Berlin, Germany
    World J Surg 31:802-7. 2007
    This study was conducted to evaluate the safety and efficacy of liver resection in patients with hepatic metastases from renal cell carcinoma and to identify selection criteria for patients suitable for resection.
  67. doi Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    James H Finke
    Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 14:6674-82. 2008
    Immune dysfunction is well documented in renal cell carcinoma (RCC) patients and likely contributes to tumor evasion...
  68. doi Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma
    Lei Li
    Institute of Urology, The 1st Affiliated Hospital, Xi an Jiaotong University, 277, YanTa Western Road, Xi an, Shaanxi 710061, China
    Cancer Lett 272:61-9. 2008
    ..However, whether it could inhibit renal cell carcinoma growth and what are the underlying mechanisms is still not well elucidated...
  69. ncbi Clinical significance of Galectin-3 in clear cell renal cell carcinoma
    Manabu Sakaki
    Department of Urology, Institute of Health Biosciences, University of Tokushima Graduated School, Tokushima, Japan
    J Med Invest 57:152-7. 2010
    ..In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological ..
  70. doi Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
    Peter Schraml
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Mod Pathol 22:31-6. 2009
    Renal cysts and clear cell renal cell carcinoma are common clinical manifestations of people with germ-line mutations of the von Hippel-Lindau tumor suppressor gene, VHL...
  71. pmc Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
    Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known...
  72. ncbi HIF-1 mediates the Warburg effect in clear cell renal carcinoma
    Gregg L Semenza
    Institute for Cell Engineering, Departments of Pediatrics, Medicine, Oncology, and Radiation Oncology, and McKusick Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Bioenerg Biomembr 39:231-4. 2007
    ..These findings delineate for the first time the molecular mechanisms underlying the Warburg effect in a human cancer...
  73. ncbi HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma
    Belén Lucas
    Institut für Zellbiologie Tumorforschung, Universitatsklinikum Essen, D 45122 Essen, Germany
    Oncogene 24:6418-31. 2005
    ..The abundance and activity of HNF4alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4alpha in renal cells...
  74. doi The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma
    Tsz fung F Chow
    Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    J Urol 183:743-51. 2010
    ..We previously identified 80 miRNAs that are dysregulated in clear cell renal cell carcinoma. In this study we validated over expression of the miR-17-92 cluster in clear cell renal cell carcinoma and ..
  75. ncbi Association of microRNA-34a overexpression with proliferation is cell type-dependent
    Khokon Kumar Dutta
    Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Kyoto 606 8501, Japan
    Cancer Sci 98:1845-52. 2007
    ....
  76. ncbi The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma
    Y Ono
    Department of Urology, Nagoya University School of Medicine and Shakaihoken Chukyo Hospital, Nagoya, Japan
    J Urol 165:1867-70. 2001
    PURPOSE: To evaluate the efficacy of laparoscopic radical nephrectomy in patients with small renal cell carcinoma, we analyzed the long-term results in those treated with laparoscopy and those undergoing open surgery...
  77. doi Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Clin Oncol 27:1280-9. 2009
    ....
  78. ncbi Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma
    Amalia A Vartanian
    N N Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
    Can J Urol 16:4726-32. 2009
    ..VM channels are revealed as periodic acid-Schiff (PAS)-positive patterns, and in some tumors their presence predicts clinical outcomes...
  79. doi Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
    Timo Purmonen
    Centre for Pharmaceutical Policy and Economics, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland
    Clin Ther 30:382-92. 2008
    Cytokine therapy is currently used as first-line treatment of metastatic renal cell carcinoma (mRCC). Until recently, treatments with proven efficacy after the failure of first-line cytokine therapy were not available...
  80. ncbi Cutaneous metastasis of renal cell carcinoma through percutaneous fine needle aspiration biopsy: case report
    Ghorbel Jilani
    Urology Department, Militairy Hospital of Tunis, 1008, Monfleury, Tunis, Tunisia
    Dermatol Online J 16:10. 2010
    A 39-year-old man, who had undergone left nephrectomy for renal cell carcinoma of clear cell type, was noted to have a solitary nodular shadow in the right lung on chest X-ray...
  81. ncbi Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma
    Natalie C Twine
    Discovery Medicine, Wyeth Research, Cambridge, Massachusetts 02140, USA
    Cancer Res 63:6069-75. 2003
    ..We identified transcripts expressed differentially between PBMCs from renal cell carcinoma patients and normal subjects, some of which appear to reflect specific immune responses of circulating ..
  82. doi Targeting mTOR in renal cell carcinoma
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer 115:2313-20. 2009
    The mammalian target of rapamycin (mTOR) is clearly an important therapeutic target for advanced renal cell carcinoma (RCC), although its mechanisms of activation are not completely understood...
  83. ncbi Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma
    Yao Zhang
    Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Yi Xue Yuan Road, Chongqing, P R China
    Int J Oncol 36:133-40. 2010
    ..The results showed that exosomes derived from IL-12-anchored renal cancer cells expressed renal cell carcinoma-associated antigen G250 and GPI-IL-12...
  84. ncbi Low adiponectin levels are associated with renal cell carcinoma: a case-control study
    Themistoklis N Spyridopoulos
    Department of Hygiene and Epidemiology, Athens University Medical School, Goudi, Athens, Greece
    Int J Cancer 120:1573-8. 2007
    ..Because obesity is a risk factor for renal cell carcinoma (RCC), we hypothesized that low adiponectin levels are associated with RCC...
  85. doi Effects of a KiSS-1 peptide, a metastasis suppressor gene, on the invasive ability of renal cell carcinoma cells through a modulation of a matrix metalloproteinase 2 expression
    Kunihiko Yoshioka
    Department of Urology, Tokyo Medical University 6 7 1 Nishi shinjuku, Shinjuku ku, Tokyo, Japan
    Life Sci 83:332-8. 2008
    ..how KiSS-1 works and to assess effects of a synthesized truncated KiSS-1 protein on the invasive ability of renal cell carcinoma (RCC) cells...
  86. doi Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis
    K Xu
    Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
    Cancer Gene Ther 17:212-22. 2010
    ..is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC)...
  87. doi Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more
    Andre Berger
    USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90080, USA
    J Urol 182:2172-6. 2009
    ..We present oncological outcomes at a followup of 10 years or greater after laparoscopic radical nephrectomy for cancer...
  88. pmc C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients
    Scott S Tykodi
    Program in Immunology, Fred Hutchinson Cancer Research Center
    Clin Cancer Res 14:5260-9. 2008
    Tumor regression has been observed in some patients with metastatic renal cell carcinoma (RCC) after nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)...
  89. doi Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials
    Grace X Zhou
    Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:257-61. 2010
    ..Recent studies found protein levels of CAIX, quantified using immunohistochemistry, correlated with clinical outcomes and therapeutic response to immunotherapy in advanced stage clear cell renal cell carcinoma (CCRCC).
  90. doi Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients
    Emilie Viey
    Institut National de la Santé et de la Recherche Médicale U753, from Institut Fédératif de Recherche 54 Villejuif, France
    J Immunother 31:313-23. 2008
    ..tumors and can be expanded as potent cytotoxic effectors from peripheral blood mononuclear cells of most renal cell carcinoma (RCC) patients, using a structural analog of nonconventional T-cell receptor gamma9delta2 ligand, ..
  91. ncbi Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma
    Yasuyoshi Miyata
    Department of Urology, Nagasaki University School of Medicine, Japan
    Clin Cancer Res 12:4876-81. 2006
    ..The clinical significance and pathologic roles of phosphorylated HGFR/c-Met in renal cell carcinoma (RCC) are not fully understood; therefore, this study sought to clarify the possible role of two tyrosine ..
  92. ncbi Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma
    Tomohiro Domoto
    Laboratory of Host Defense, University of Shizuoka, Shizuoka, Japan
    Cancer Sci 98:77-82. 2007
    This study aimed to analyze expression of S100A10, annexin II and B-FABP genes in renal cell carcinoma (RCC) and their potential value as tumor markers...
  93. doi Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC).
  94. doi Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Cancer Treat Rev 36:16-23. 2010
    Five targeted agents have shown efficacy in advanced renal cell carcinoma. These agents were evaluated in pivotal phase III clinical trials using different treatment settings and different patient populations...
  95. doi Unusual solitary metastasis of the ciliary body in renal cell carcinoma
    Vito Mancini
    Urology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation DETO, University of Bari, Italy
    Int J Urol 15:363-5. 2008
    b>Renal cell carcinoma (RCC) usually metastasizes to the lung, liver, bone; ocular metastasis is uncommon...
  96. pmc Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, Pennsylvania 18015, USA
    Oncologist 15:236-45. 2010
    Historically, there have been few treatment options for patients with advanced renal cell carcinoma (RCC) besides immunotherapy with interleukin-2 and interferon (IFN)-alpha...
  97. ncbi Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma
    Rainer Riesenberg
    Tumor Immunology Laboratory, LIFE Center, Department of Urology, University Clinic Grosshadern, Institute of Pathology, Ludwig Maximilians University Munich, Munich, Germany
    Clin Cancer Res 13:6993-7002. 2007
    ..Here, we analyzed the role of IDO in tumor growth and disease progression in patients with clear cell renal cell carcinoma (RCC).
  98. doi Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
    Annika Berntsen
    Department of Oncology Section, Center for Cancer Immunotherapy, Herlev Hospital, Herlev, Denmark
    J Immunother 31:771-80. 2008
    ..T-cell response, and clinical response after treatment with a DC-based vaccine in patients with metastatic renal cell carcinoma. Twenty-seven patients with progressive cytokine-refractory metastatic renal cell carcinoma were vaccinated ..
  99. doi Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN
    Emma R Woodward
    Cancer Research UK Renal Molecular Oncology Group and Department of Medical and Molecular Genetics, University of Birmingham and West Midlands Regional Genetics Service, Birmingham Women s Hospital, United Kingdom
    Clin Cancer Res 14:5925-30. 2008
    Familial renal cell carcinoma (RCC) is genetically heterogeneous. The most common histopathologic subtype of sporadic and familial RCC is clear cell (cRCC) and von Hippel-Lindau (VHL) disease is the most common cause of inherited cRCC...
  100. pmc Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study
    Hans J Hammers
    Johns Hopkins University, Baltimore, Maryland, USA
    Mol Cancer Ther 9:1525-35. 2010
    ..of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients...
  101. pmc Robotic assisted laparoscopic partial nephrectomy for suspected renal cell carcinoma: retrospective review of surgical outcomes of 35 cases
    Sam B Bhayani
    Department of Surgery, Division of Urology, Washington University School of Medicine, Saint Louis, MO, USA
    BMC Surg 8:16. 2008
    ..Robotic assistance may augment partial nephrectomy by aiding in dissection and renal reconstruction. In this communication we describe the surgical outcomes of 35 patients undergoing robotic partial nephrectomy...

Research Grants82

  1. Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer
    Roberto Pili; Fiscal Year: 2007
    Tumor angiogenesis is critical for the development and progression of epithelial tumors including renal cell carcinoma (RCC)...
  2. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    EUGENE D contact KWON; Fiscal Year: 2010
    b>Renal cell carcinoma (RCC) encompasses 90% of kidney cancers and 3% of adult cancers. In the U.S. alone, more than 30,000 new cases of RCC are diagnosed and nearly 13,000 patients die from RCC annually...
  3. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    Eugene Kwon; Fiscal Year: 2009
    b>Renal cell carcinoma (RCC) encompasses 90% of kidney cancers and 3% of adult cancers. In the U.S. alone, more than 30,000 new cases of RCC are diagnosed and nearly 13,000 patients die from RCC annually...
  4. Regulation of nitrogen catabolic gene expression in S cerevisiae
    TERRANCE COOPER; Fiscal Year: 2007
    ..coronary artery disease, as antineoplastic agents in the treatment of estrogen-induced breast cancer and renal cell carcinoma, and as immunosuppressants following organ transplant surgery. In S...
  5. Regulation of nitrogen catabolic gene expression in S cerevisiae
    Terrance G Cooper; Fiscal Year: 2010
    ..coronary artery disease, as antineoplastic agents in the treatment of estrogen-induced breast cancer and renal cell carcinoma, and as immunosuppressants following organ transplant surgery. In S...
  6. PAX2 INTERACTING PROTEINS IN DEVELOPMENT AND DISEASE
    Gregory Dressler; Fiscal Year: 2009
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, inluuding renal cell carcinoma, polycystic kidney disease, Wilms' tumor, and prostate carcinoma...
  7. Systemic AA Amyloidosis Inhibitors
    ALAN SNOW; Fiscal Year: 2004
    ..ankylosing spondylitis, inflammatory bowel diseases, tuberculosis, leprosy, Hodgkin's disease, renal cell carcinoma, and Familial Mediterranean Fever...
  8. Mechanism of Gene Repression in the Kidney
    SANJEEVKUMAR PATEL; Fiscal Year: 2009
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, including renal cell carcinoma, polycystic kidney disease, Wilms' tumor, and prostate carcinoma...
  9. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2010
    ..by epithelial cell dedifferentiation: ischemia, toxic renal injury, polycystic kidney disease and renal cell carcinoma. It is upregulated more than any other known protein with renal injury...
  10. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    Joseph Bonventre; Fiscal Year: 2007
    ..by epithelial cell dedifferentiation: ischemia, toxic renal injury, polycystic kidney disease and renal cell carcinoma. It is upregulated more than any other known protein with renal injury...
  11. REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCER
    Debabrata Mukhopadhyay; Fiscal Year: 2009
    Most of the cases, the clear-cell renal cell carcinoma (RCC) express strikingly elevated baseline levels of vascular permeability factor also known as vascular endothelial growth factor (VEGF) rationalized their vascular nature...
  12. REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCER
    Debabrata Mukhopadhyay; Fiscal Year: 2010
    Most of the cases, the clear-cell renal cell carcinoma (RCC) express strikingly elevated baseline levels of vascular permeability factor also known as vascular endothelial growth factor (VEGF) rationalized their vascular nature...
  13. Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Othon Iliopoulos; Fiscal Year: 2010
    The incidence of renal cell carcinoma (RCC) in United States has been projected to reach 56,000 cases/year in 2007 and has been rising since 1970 for both men and women and for whites as well as blacks...
  14. PAX2 INTERACTING PROTEINS IN DEVELOPMENT AND DISEASE
    Gregory R Dressler; Fiscal Year: 2010
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, inluuding renal cell carcinoma, polycystic kidney disease, Wilms'tumor, and prostate carcinoma...
  15. Mechanism of Gene Repression in the Kidney
    Sanjeevkumar R Patel; Fiscal Year: 2010
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, including renal cell carcinoma, polycystic kidney disease, Wilms'tumor, and prostate carcinoma...
  16. Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
    Tricia Wright; Fiscal Year: 2007
    b>Renal cell carcinoma (RCC), a notoriously hard to treat solid tumor and the most common form of kidney cancer, has minimal sensitivity to traditional chemotherapy...
  17. Genetic Susceptibility Modifiers in Renal Cell Carcinoma
    Xifeng Wu; Fiscal Year: 2007
    ..Tobacco exposure is an established risk factor for renal cell carcinoma (RCC)...
  18. A Schizosaccharomyces pombe Model of Birt-Hogg-Dube Syndrome
    ELIZABETH HENSKE; Fiscal Year: 2007
    ..an autosomal dominant disorder characterized by skin hamartomas, lung cysts, spontaneous pneumothorax, and renal cell carcinoma. A germline mutation in the BHD gene was also recently found in a large kindred with dominantly inherited ..
  19. Genotype and phenotype predictors in therapy response in renal cell carcinoma
    Katherine L Nathanson; Fiscal Year: 2010
    Therapy of renal cell carcinoma (RCC) has been transformed in recent years by the efficacy of targeted agents that inhibit kinases involved in critical cellular signaling pathways and VEGF, a primary driver of tumor angiogenesis...
  20. MOLECULAR-GENETIC ANALYSIS OF 3P14 GENOMIC STABILITY
    Harry Drabkin; Fiscal Year: 2006
    ..rearrangement of any protein that interacts with VHL and its function may be germane to the development of renal cell carcinoma (RCC)...
  21. Genotype and phenotype predictors in therapy response in renal cell carcinoma
    William Lee; Fiscal Year: 2009
    Therapy of renal cell carcinoma (RCC) has been transformed in recent years by the efficacy of targeted agents that inhibit kinases involved in critical cellular signaling pathways and VEGF, a primary driver of tumor angiogenesis...
  22. TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
    Thomas S Griffith; Fiscal Year: 2010
    This year in the U.S. ~40,000 new cases of renal cell carcinoma (RCC) will be diagnosed and >13,000 deaths are expected from RCC...
  23. TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
    THOMAS GRIFFITH; Fiscal Year: 2009
    This year in the U.S. ~40,000 new cases of renal cell carcinoma (RCC) will be diagnosed and >13,000 deaths are expected from RCC...
  24. Wnt antagonist genes in kidney tumor progression and metastasis
    Rajvir Dahiya; Fiscal Year: 2010
    ..whether inactivation of Wnt antagonist genes is involved in the progression and metastasis of human renal cell carcinoma. Based on the preliminary data, we have screened several Wnt antagonist genes and have identified six genes ..
  25. Analysis of Somatic Mutations in Cancer of the Kidney
    WAYNE VEDECKIS; Fiscal Year: 2005
    ..in p53 result from tobacco smoke carcinogens), and because we have access to DNA from 1,141 newly diagnosed renal cell carcinoma cases in the INCO Central Europe Health Study (CEHS), this NCI R03 project will evaluate whether there is a ..
  26. Genetic Retargeted Human T-cells for RCC Immunotherapy
    Wayne Marasco; Fiscal Year: 2006
    b>Renal cell carcinoma (RCC) is the most prevalent malignancy within the kidney and the incidence is rising. Due to improved radiological evaluation, over 50% of the renal cancers are found incidentally...
  27. MDA-7/IL-24 and free radicals in renal cancer therapy
    Paul Dent; Fiscal Year: 2009
    b>Renal Cell Carcinoma (RCC) is among the most lethal and difficult tumors to treat, particularly when disease has spread beyond the kidney and into the surrounding fascia; even intensive combinations of radio- and chemotherapy are not ..
  28. MDA-7/IL-24 and free radicals in renal cancer therapy
    Paul Dent; Fiscal Year: 2007
    b>Renal Cell Carcinoma (RCC) is among the most lethal and difficult tumors to treat, particularly when disease has spread beyond the kidney and into the surrounding fascia; even intensive combinations of radio- and chemotherapy are not ..
  29. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2010
    ..in various states characterized by epithelial cell dedifferentiation: ischemia, toxic renal injury, and renal cell carcinoma. We have cloned, and generated monoclonal and polyclonal antibodies to, the human, mouse, pig, dog, ..
  30. Predictive Markers in Metastatic Renal Cancer
    Frederic M Waldman; Fiscal Year: 2010
    Metastatic renal cell carcinoma (RCC) is a dismal disease, with nearly uniform resistance to radiotherapy, chemotherapy and immunotherapy...
  31. Predictive Markers in Metastatic Renal Cancer
    Frederic Waldman; Fiscal Year: 2009
    Metastatic renal cell carcinoma (RCC) is a dismal disease, with nearly uniform resistance to radiotherapy, chemotherapy and immunotherapy...
  32. Allogeneic T Cell Responses Against Renal Cell Carcinoma
    Edus Warren; Fiscal Year: 2007
    b>Renal cell carcinoma (RCC) is distinguished amongst solid tumors for its resistance to conventional chemo- and radiotherapy but its susceptibility, in a minority of patients, to immunologic manipulation...
  33. Targeting Novel T Cell Antigens on Renal Cell Carcinoma
    SCOTT TYKODI; Fiscal Year: 2007
    Metastatic renal cell carcinoma (RCC) is poorly responsive to most conventional cancer therapy, but regression of metastatic RCC is seen in 10-20% of patients treated with non-specific immunotherapies such as interleukin-2 or interferon-(..